Mitral Valve Disease Market Expected to Reach $5.7 Billion by 2031—Allied Market Research

According to a new report published by Allied Market Research, titled, “Mitral Valve Disease Market," The mitral valve disease market size was valued at $2.5 billion in 2021, and is estimated to reach $5.7 billion by 2031, growing at a CAGR of 8.8% from 2022 to 2031. The increase in the prevalence of mitral valve diseases and the development of advanced technologies for mitral valve are some treatment act as the key mitral valve disease market trends for growth of market.

In addition, the surge in demand for minimally invasive surgeries for the treatment of malfunctioned mitral valves is a significant factor that fuels the mitral valve disease market size. This is attributed to the fact that traditional open-heart surgery for mitral valve replacement is a highly invasive procedure that requires prolonged recovery time and carries a significant risk of complications.

In contrast, minimally invasive surgeries, such as transcatheter mitral valve replacement (TMVR), involve much smaller incisions and result in faster recovery with fewer complications. Thus, the demand for minimally invasive procedures is driven by a number of factors, including patient preference, improved safety & efficacy, and advancements in technology. Moreover, minimally invasive mitral valve treatment procedures allow shorter hospital stays and reduced healthcare costs, thus increasing their preference among healthcare providers and mitral valve disease patients. As the demand for minimally invasive procedures continues to grow, the market for mitral valve disease is expected to expand significantly.

On the basis of treatment type, the market is segregated into mitral valve repair, mitral valve replacement, cardiac resynchronization therapy (CRT), and mitral valve therapeutics. The mitral valve repair segment dominated the mitral valve disease market share in terms of revenue in 2021 due to lower risk of complications, preservation of the native heart valve, shorter recovery time, and prevention of lifelong anticoagulant therapy. Mitral valve repair involves repairing the patient's own native valve rather than replacing it with an artificial valve. In addition, repair procedure is considered a less invasive procedure, and it carries a lower risk of complications such as bleeding, infection, and stroke. 

Depending on indication, the market is classified into mitral valve stenosis, mitral valve prolapse, and mitral valve regurgitation. The mitral valve regurgitation segment dominated the market in terms of revenue in 2021, owing to increase in incidence of mitral valve regurgitation. In addition, surge in geriatric population notably contributes toward the growth of this segment. This is attributed to the fact that elderly individuals are highly susceptible to develop mitral valve regurgitation. Moreover, rise in application of CRT in the treatment of mitral valve regurgitation is augmenting the market growth.

On the other hand, the mitral valve stenosis segment is anticipated to exhibit the fastest growth during the forecast period, owing to increase in prevalence of mitral valve stenosis among the population. This condition is often associated with rheumatic disease caused by an untreated streptococcal infection, which can damage the heart valve and potentially lead to heart failure. Thus, people seek efficient options for the treatment of mitral valve stenosis such as medications, repair, replacement, and CRT, which will contribute to the growth of the mitral valve stenosis segment. 

By end user, the market is categorized into hospitals, ambulatory surgical centers, and others. In 2021, the hospitals segment recorded the highest revenue growth in mitral valve disease market and is expected to continue to grow at a faster rate during the mitral valve disease market analysis. This is attributed to the fact that hospitals have proven to be more equipped to provide a higher level of care compared to ambulatory surgical centers, which is causing the shift of people toward it for mitral valve disease treatment.

Region wise, North America accounted for the largest mitral valve disease market share  in terms of revenue in 2021, due to alarming increase in the incidence of valvular heart diseases, including mitral valve disease, in the region. This can be attributed to factors such as sedentary lifestyle, unhealthy eating habits, and rise in aging population. In addition, surge in demand for mitral valve disease treatment products and minimally invasive procedures is driving the market growth.

Furthermore, the availability of skilled professionals and advancements in heart valve technologies have made it possible to perform more complex mitral valve procedures with higher success rates, leading to increased demand for these treatments in North America.

On the other hand, Asia-Pacific is expected to witness the highest growth during the mitral valve disease market forecast period due to surge in demand for minimally invasive mitral valve procedures to address the unmet needs of a large population. In addition, the development of healthcare infrastructure, rise in healthcare reforms, and increase in healthcare expenditure in emerging economies are anticipated to contribute toward the growth of the mitral valve disease market in Asia-Pacific. 
 
Key findings of the study
• On the basis of treatment type, the mitral valve repair segment was highest contributor to the market in 2021; however, the mitral valve replacement segment is anticipated to grow at the fastest rate during the forecast period.
• Depending on indication, the mitral valve regurgitation segment dominated the mitral valve disease industry in 2021; however, the mitral valve stenosis segment is anticipated to grow at the highest CAGR in the coming future.
• By end user, the hospitals segment led the mitral valve disease industry in 2021 and is anticipated to grow at the highest CAGR.
• Region wise, North America generated the largest revenue in 2021. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.